Change in number of shares and votes in Aerocrine
With reference to Chapter 4 Section 9 in ”lagen (1991:980) om handel med finansiella instrument” it’s hereby announced that through the subscription by exercise of options in Aerocrine the number of shares and votes in Aerocrine has increased during March 2013 as specified in the table below.
|Number of shares and votes|
|March 1, 2013||145 637 781|
|March 28, 2013||145 956 405|
Solna March 28, 2013
Aerocrine AB (publ.)
For further information, please contact:
Michael Colérus, CFO, +46 8 629 07 85
Aerocrine AB is a medical products company focused on improved management and care of patients with inflammatory airway diseases such as Asthma. Within this sector, Aerocrine is the world leader. Aerocrine markets NIOX MINO®, which enables fast and reliable point-of-care measurement of airway inflammation. This product plays a critical role in more effective diagnosis, treatment and follow-up of patients affected with inflammatory airway diseases. Aerocrine is based in Sweden with subsidiaries in the US, Germany, Switzerland and the UK. Aerocrine shares have been listed on the Stockholm Stock Exchange since 2007 (AERO-B.ST). For more information please visit www.aerocrine.com and www.niox.com.
|Aerocrine may be required to disclose the information provided herein pursuant to the Securities Markets Act and/or the Financial Instruments Trading Act. The information was submitted for publication at 08:00 am on March 28, 2013.|